Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis

  • Chi-Huang Chen
  • Chii-Ruey Tzeng
  • Peng-Hui Wang
  • Wei-Min Liu
  • Heng-Yu Chang
  • Huang-Hui Chen
  • Ching-Hui Chen
Review
  • 56 Downloads

Abstract

Purpose

To summarize available evidence from randomized-controlled trials which have evaluated triggering of final oocyte maturation with concomitant GnRH agonists and hCG in patients undergoing IVF, and to analyze whether dual triggering is as efficacious as hCG triggering in terms of oocyte and pregnancy outcomes.

Methods

A comprehensive literature search was performed to identify randomized-controlled trials comparing IVF outcomes between women receiving combined administration of hCG with GnRH agonists and those receiving hCG alone for triggering of final oocyte maturation.

Results

Four studies including 527 patients eligible for inclusion in meta-analysis were identified. No significant difference in the number of mature oocytes or fertilized oocytes retrieved was found between groups. Clinical pregnancy rate with dual triggering was significantly higher as compared with hCG-alone triggering (pooled OR = 0.48, 95% CI 0.31–0.77, P = 0.002), but there was no significant difference in the ongoing pregnancy rate between groups.

Conclusion

Results of meta-analysis indicate comparable or significantly improved outcomes with the use of GnRH agonists plus hCG as compared with hCG alone for triggering of final oocyte maturation.

Keywords

GnRH agonist plus hCG hCG In vitro fertilization Ovarian hyperstimulation syndrome 

Notes

Acknowledgements

None.

Authors’ contributions

C-HuangC: project development and data analysis. CRT, PHW, WML, HYC, and HHC: Data collection and data analysis. C-HuiC: project development, data collection, data analysis, and manuscript writing.

Compliance with ethical standards

Conflict of interest

The authors declare they have no known conflicts of interest in this work.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Youssef MA, Van der Veen F, Al-Inany HG et al (2014) Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 10:CD008046Google Scholar
  2. 2.
    Babayof R, Margalioth EJ, Huleihel M et al (2006) Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 21:1260–1265CrossRefPubMedGoogle Scholar
  3. 3.
    Humaidan P, Bredkjaer HE, Bungum L et al (2005) GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 20:1213–1220CrossRefPubMedGoogle Scholar
  4. 4.
    Humaidan P, Bungum L, Bungum M, Andersen CY (2006) Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 13:173–178CrossRefPubMedGoogle Scholar
  5. 5.
    Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C (2010) 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 93:847–854CrossRefPubMedGoogle Scholar
  6. 6.
    Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H (2011) A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 95:1174–1177CrossRefPubMedGoogle Scholar
  7. 7.
    Kasum M, Kurdija K, Orešković S, Čehić E, Pavičić-Baldani D, Škrgatić L (2016) Combined ovulation triggering with GnRH agonist and hCG in IVF patients. Gynecol Endocrinol 8:1–5Google Scholar
  8. 8.
    Fauser BC, de Jong D, Olivennes F et al (2002) Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 87:709–715CrossRefPubMedGoogle Scholar
  9. 9.
    Decleer W, Osmanagaoglu K, Seynhave B, Kolibianakis S, Tarlatzis B, Devroey P (2014) Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts Views Vis ObGyn 6:203–209PubMedPubMedCentralGoogle Scholar
  10. 10.
    Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM (2014) Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med 59:63–68PubMedGoogle Scholar
  11. 11.
    Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, Raziel A (2008) Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril 90:1087–1093CrossRefPubMedGoogle Scholar
  12. 12.
    Mahajan N, Sharma S, Arora PR, Gupta S, Rani K, Naidu P (2016) Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: a prospective randomized study. J Hum Reprod Sci 9:101–106CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Iñarra MJ, Crisol L, Guembe MA (2015) Use of dual trigger with gonadotropin-releasing hormone agonist (GnRH-a) and human chorionic gonadotropin (hCG) to optimize oocyte recovery rates and IVF results. In: European Society of Reproduction and Embryology 2015 Annual Meeting; June 2015; Lisbon, PortugalGoogle Scholar
  14. 14.
    Cochrane Handbook for Systematic Reviews of interventions. Version 5.1.0. (updated March, 2011). The Cochrane Collaboration. http://training.cochrane.org/handbook
  15. 15.
    Hardy RJ, Thompson SG (1998) Detecting and describing heterogeneity in meta-analysis. Stat Med 17:841–856CrossRefPubMedGoogle Scholar
  16. 16.
    Takkouche B, Cadarso-Suárez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150:206–215CrossRefPubMedGoogle Scholar
  17. 17.
    National Research Council (1992) Combing information: statistical issues and opportunities for research. National Academy Press, Washington, DCGoogle Scholar
  18. 18.
    Sterne JA, Sutton AJ, Ioannidis JP et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 22(343):d4002CrossRefGoogle Scholar
  19. 19.
    Erb TM, Vitek W, Wakim AN (2010) Gonadotropin-releasing hormone agonist or human chorionic gonadotropin for final oocyte maturation in an oocyte donor program. Fertil Steril 93:374–378CrossRefPubMedGoogle Scholar
  20. 20.
    Imoedemhe DA, Sigue AB, Pacpaco EL, Olazo AB (1991) Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 55:328–332CrossRefPubMedGoogle Scholar
  21. 21.
    Gonen Y, Balakier H, Powell W, Casper RF (1990) Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71:918–922CrossRefPubMedGoogle Scholar
  22. 22.
    Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM (2013) Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril 100:1296–1302CrossRefPubMedGoogle Scholar
  23. 23.
    Pereira N, Elias RT, Neri QV et al (2016) Adjuvant gonadotrophin-releasing hormone agonist trigger with human chorionic gonadotrophin to enhance ooplasmic maturity. Reprod Biomed Online 33:568–574CrossRefPubMedGoogle Scholar
  24. 24.
    Seval MM, Özmen B, Atabekoğlu C et al (2016) Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. J Obstet Gynaecol Res 42:1146–1151CrossRefPubMedGoogle Scholar
  25. 25.
    Lu X, Hong Q, Sun L et al (2016) Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. Fertil Steril 106:1356–1362CrossRefPubMedGoogle Scholar
  26. 26.
    Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ (2016) Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 4:CD001750PubMedGoogle Scholar
  27. 27.
    Beckers T, Bernd M, Kutscher B, Kühne R, Hoffmann S, Reissmann T (2001) Structure-function studies of linear and cyclized peptide antagonists of the GnRH receptor. Biochem Biophys Res Commun 289:653–663CrossRefPubMedGoogle Scholar
  28. 28.
    Kolibianakis EM, Schultze-Mosgau A, Schroer A (2005) A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20:2887–2892CrossRefPubMedGoogle Scholar
  29. 29.
    Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C (2008) The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 89:84–91CrossRefPubMedGoogle Scholar
  30. 30.
    Kol S, Humaidan P, Alsbjerg B et al (2015) The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors. Reprod Biomed Online 30:563–565CrossRefPubMedGoogle Scholar
  31. 31.
    Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C (2011) Comparison of “triggers” using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril 95:2715–2717CrossRefPubMedGoogle Scholar
  32. 32.
    Humaidan P, Kol S, Papanikolaou EG, Copenhagen GnRH Agonist Triggering Workshop Group (2011) GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 17:510–524CrossRefPubMedGoogle Scholar
  33. 33.
    Boothroyd C, Karia S, Andreadis N, Rombauts L, Johnson N, Chapman M, Australasian CREI Consensus Expert Panel on Trial evidence (ACCEPT) group (2015) Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. Aust N Z J Obstet Gynaecol 55:523–534CrossRefPubMedGoogle Scholar
  34. 34.
    Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L (2012) Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 97:1316–1320CrossRefPubMedGoogle Scholar
  35. 35.
    O’Neill KE, Senapati S, Maina I, Gracia C, Dokras A (2016) GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet 33:1175–1184CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyTaipei Medical University HospitalTaipeiTaiwan
  2. 2.Department of Obstetrics and Gynecology, School of Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  3. 3.Department of Obstetrics and GynecologyTaipei Veterans General HospitalTaipeiTaiwan
  4. 4.Department of Obstetrics and Gynecology, School of MedicineNational Yang-Ming UniversityTaipeiTaiwan
  5. 5.Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  6. 6.Graduate Institute of Medical Sciences, College of MedicineTaipei Medical UniversityTaipeiTaiwan
  7. 7.Department of Obstetrics and GynecologyTaipei Medical University Hospital and Taipei Medical UniversityTaipeiTaiwan

Personalised recommendations